PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

John H. Strickler,Fang Shu Ou,Tanios Bekaii-Saab,Christine Megerdichian Parseghian,Andrea Cercek,Kimmie Ng,Federico Augusto Sanchez,Sarah Bruggeman,Joseph J. Larson,Gene Grant Finley,Joleen M Hubbard,Christina Wu,Heinz-Josef Lenz,Scott Kopetz,Ryan B. Corcoran

PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

2021

John H. Strickler
Fang Shu Ou
Tanios Bekaii-Saab
Christine Megerdichian Parseghian
Andrea Cercek
Kimmie Ng
Federico Augusto Sanchez
Sarah Bruggeman
Joseph J. Larson
Gene Grant Finley
Joleen M Hubbard
Christina Wu
Heinz-Josef Lenz
Scott Kopetz
Ryan B. Corcoran

TPS143Background: Patients with KRAS and NRAS (RAS) wild-type mCRC benefit from the epidermal growth factor receptor (EGFR) monoclonal antibodies (Abs) panitumumab and cetuximab, but nearly all pat...

Keywords:

KRAS
Colorectal cancer
Cancer research
Cetuximab
Panitumumab
Wild type
Monoclonal antibody
Epidermal growth factor receptor
Neuroblastoma RAS viral oncogene homolog
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations